STAT Plus: The good, the bad, and the really, really ugly behind Sarepta’s drug approval
RUBY WALLAU FOR STAT
What does it all mean now that the FDA has issued a surprise decision to approve Sarepta Therapeutics’ Duchenne muscular dystrophy drug?
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario